Xianhai Huang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7543251/publications.pdf

Version: 2024-02-01

19	362	840776 11	794594 19
papers	citations	h-index	g-index

22	22	22	385
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cyclic Hydroxyamidines as Amide Isosteres: Discovery of Oxadiazolines and Oxadiazines as Potent and Highly Efficacious Î³-Secretase Modulators in Vivo. Journal of Medicinal Chemistry, 2012, 55, 489-502.	6.4	52
2	Synthesis and SAR Studies of Fused Oxadiazines as Î³-Secretase Modulators for Treatment of Alzheimer's Disease. ACS Medicinal Chemistry Letters, 2012, 3, 931-935.	2.8	34
3	Discovery of a Potent Pyrazolopyridine Series of Î³-Secretase Modulators. ACS Medicinal Chemistry Letters, 2011, 2, 471-476.	2.8	33
4	The Discovery of Pyridone and Pyridazone Heterocycles as Î³-Secretase Modulators. ACS Medicinal Chemistry Letters, 2010, 1, 184-187.	2.8	32
5	Discovery of fused 5,6-bicyclic heterocycles as Î³-secretase modulators. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 664-669.	2.2	26
6	The discovery of fused oxadiazepines as gamma secretase modulators for treatment of Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 466-471.	2.2	23
7	Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. ACS Medicinal Chemistry Letters, 2012, 3, 63-68.	2.8	22
8	Discovery of a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. ACS Medicinal Chemistry Letters, 2011, 2, 171-176.	2.8	20
9	A three-step protocol for lead optimization: Quick identification of key conformational features and functional groups in the SAR studies of non-ATP competitive MK2 (MAPKAPK2) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 65-70.	2.2	20
10	Conformation constraint of anilides enabling the discovery of tricyclic lactams as potent MK2 non-ATP competitive inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3262-3266.	2.2	20
11	Discovery of a Potent Dihydrooxadiazole Series of Non-ATP-Competitive MK2 (MAPKAPK2) Inhibitors. ACS Medicinal Chemistry Letters, 2012, 3, 100-105.	2.8	13
12	SAR studies of C2 ethers of 2H-pyrano[2,3-d]pyrimidine-2,4,7(1H,3H)-triones as nicotinic acid receptor (NAR) agonist. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 854-858.	2.2	12
13	Efficient and regioselective synthesis of pyrimido[5,4-d]pyrimidine-2,4,6,8(1H,3H,5H,7H)-tetraones with diversified substitutions. Tetrahedron Letters, 2012, 53, 7154-7158.	1.4	10
14	Discovery of MK-8318, a Potent and Selective CRTh2 Receptor Antagonist for the Treatment of Asthma. ACS Medicinal Chemistry Letters, 2018, 9, 679-684.	2.8	10
15	Discovery of a Tetrahydrobenzisoxazole Series of Î³-Secretase Modulators. ACS Medicinal Chemistry Letters, 2017, 8, 1002-1006.	2.8	9
16	Efficient synthesis and reaction pathway studies of novel fused morpholine oxadiazolines for use as gamma secretase modulators. Tetrahedron Letters, 2012, 53, 6451-6455.	1.4	8
17	Generation of Leads for Î³-Secretase Modulation. Journal of Medicinal Chemistry, 2020, 63, 8216-8230.	6.4	7
18	The synthesis of 2,3,6-trisubstituted 1-oxo-1,2-dihydroisoquinolines as potent CRTh 2 antagonists. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 5344-5348.	2.2	6

#	Article	IF	Citations
19	A Case Study of Singleâ€Pill Combination Therapy: The Ezetimibe/Simvastatin Combination for Treatment of Hyperlipidemia. ChemMedChem, 2012, 7, 1882-1894.	3.2	5